CLINICAL_TRIALS ClinicalTrials.gov record update

Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE")

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01524926
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:25.567088+00:00
Published At: 2023-12-11T00:00:00+00:00
Record Updated At: 2023-12-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma", "Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor", "Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1", "Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma", "Locally Advanced and/or Metastatic Clear Cell Sarcoma", "Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-12-11"
protocolSection.identificationModule.nctId: "NCT01524926"
protocolSection.identificationModule.officialTitle: "Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET (\"CREATE\")"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.